Premium
Ventyx Biosciences Inc (VTYX)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Show more
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.015 | 0.742574257426 | 2.02 | 2.095 | 1.83 | 1387364 | 1.96601499 | CS |
| 4 | -0.325 | -13.7711864407 | 2.36 | 2.605 | 1.83 | 1855796 | 2.23326671 | CS |
| 12 | -0.315 | -13.4042553191 | 2.35 | 3.39 | 1.67 | 1755597 | 2.33670049 | CS |
| 26 | -0.535 | -20.8171206226 | 2.57 | 3.39 | 1.67 | 1422969 | 2.29979759 | CS |
| 52 | 0.075 | 3.82653061224 | 1.96 | 11.48 | 1.67 | 1985480 | 4.19892526 | CS |
| 156 | -12.175 | -85.6790992259 | 14.21 | 47.2508 | 1.67 | 1247010 | 11.25614687 | CS |
| 260 | -16.615 | -89.0884718499 | 18.65 | 47.2508 | 1.67 | 1169225 | 11.37032298 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
